The Middle East and Africa IVF Market size is expected to reach USD 0.55 billion by 2027 from USD 0.26 billion in 2022, growing at a CAGR of 16.64% from 2022 to 2027.
The high rate of healthcare GDP, increase in the average age of the first child, drop-in infertility rates, rising cases of young people suffering from non-communicable diseases such as polycystic ovary syndrome, diabetes, increasing incidence of obesity, favorable fertility tourism, and government initiatives are the factor responsible for the positive growth of the MEA IVF market. However, globally, the birth rate is declining due to various factors such as the increasing age-related infertility and preference for late marriage and children. According to the United Nations, the UAE's current birth rate in 2022 is 10,112 births per 1,000 people, down 0.88% from 2020. In 2020, the regional birth rate was at 10,200 births per 1,000 people, down by 0.88% from the year 2019. While in 2019, the birth rate was recorded at 10,291 births per 1,000 people, down 0.87% from 2018. Thus, the decline in the birth rate can be attributed to rising in infertility, leading to a significant increase in demand for IVF treatments for both men and females.
In women, the chances of conceiving decrease after age 32, and by the age of 40, fertility rates are halved; likewise, in men between the ages of 20 and 80, semen volume and sperm motility decrease. Therefore, women who delay pregnancy are at increased risk of low birth weight, miscarriage, fetal abnormalities, premature labor, still birth, prolonged labor, and maternal morbidity. According to a new report, the fertility rate across the globe was at 10%, and the percentage was at a high of 15% or more in the Middle East and African region. Also, infertility in males is growing with an increased number of nearly 50%, and these cases are due to lifestyle, lack of exercise, diabetes, obesity, and genetics-related factors. All the factors mentioned above are anticipated to drive the MEA IVF market for the next few years.
According to a study from the Advanced Fertility Center in Chicago, 1 in 4 women is infertile by 35. The study indicates that the pregnancy rate gradually declines in your 30s and drops sharply over the past 30 and 40 years. Additionally, it can be noted that the success rate of a single IVF cycle is limited, where many couples try multiple processes. Decreasing the success rates of IVF treatment procedures with increasing patient age is a significant challenge for fertility treatment technologies. Additionally, complications associated with IVF treatment and inadequate reimbursement options will restraint the market during the forecast period.
This research report on the Middle East and Africa IVF Market has been segmented and sub-segmented into the following categories:
By Reagents and Media:
By End Users:
Geographically, the Saudi Arabian market is expected to be the largest market share in the MEA IVF market. This market growth can be attributed to the decline in the birth rate, the growing number of government-backed fertility clinics and infertility services, and increased product launches are expected to boost the regional market. Saudi Arabia's current birth rate in 2022 is 16,630 births per 1,000 people, a decrease of 2.73% from 2020. While in the year 2020, the birth rate was at 17,097 births per 1,000 people, a reduction of 2.65% compared to 2019. The markets are anticipated to grow and gather new opportunities with collaborations between international players and the regional government for healthcare awareness.
In the UAE, the regional market will grow with the highest CAGR during the projected period, owing to increasing rates of obesity and polycystic ovary syndrome, delayed marriages, better reimbursement policies, and increased IVF tourism. According to a recent report, medical tourism represents 12 to 16% of the volume of IVF patients. Additionally, the growing number of product launches and medications are expected to boost the UAE IVF market.
KEY MARKET PLAYERS:
Companies playing a notable role in the MEA IVF Market covered in this report are CooperSurgical, Inc. (U.S.), Vitrolife AB (Sweden), Cook Medical, Inc. (U.S.), Irvine Scientific (U.S.), Thermo Fisher Scientific, Inc. (U.S.), EMD Serono, Inc. (U.S.), Genea Limited (Australia), ESCO Micro Pte. Limited (Singapore), IVFtech ApS (Denmark), and The Baker Company, Inc. (U.S.).
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: firstname.lastname@example.org